Form 4: Atossa Therapeutics Director, Tessa Cigler, Acquires Stock Options
SEC Form 4 Filing
Director Tessa Cigler acquired stock options in Atossa Therapeutics, according to a recent SEC filing.
Summary
- Tessa Cigler, a director at Atossa Therapeutics, acquired stock options on May 15, 2025.
- The options grant the right to buy 125,000 shares of common stock at an exercise price of $0.99 per share.
- The options vest quarterly over 12 months, contingent upon continued service.
- The options expire on May 15, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The granting of stock options to a director is a routine event, but it can signal confidence in the company's future.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.
Stakeholder Impact
- The stock option grant could potentially impact shareholders by diluting ownership if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of the stock option grant and earliest transaction date. |
| 05/16/2025 | Date of signature on the SEC filing. |
| 05/15/2035 | Expiration date of the stock options. |
Keywords
Atossa Therapeutics, Stock Options, Director, Tessa Cigler, SEC Filing, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.